Roche launches antibodies to ID mutations in brain cancer

Create PDF

Feb. 27, 2023—Roche launched the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and ATRX Rabbit Polyclonal Antibody to identify mutation status in patients who have brain cancer.

The IDH1 assay can detect the IDH1 R132H mutation in adult-type gliomas and acute myeloid leukemia. When present, IDH1 R132H is associated with a relatively favorable prognosis and is important in patient stratification for clinical trials. The ATRX assay detects a mutation in the ATRX gene, providing diagnostic and prognostic information to clinicians.